Navigation Links
Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis

Aim is to Target 46,000,000 Atopic Patients Worldwide

FERNDALE, Michigan and NESS ZIONA, Israel, June 3 /PRNewswire/ -- Ferndale Laboratories Inc. and Foamix Ltd. announced today that the two companies executed a license agreement for Ferndale to develop and commercialize non-steroidal foam for the treatment of atopic dermatitis and eczema.

The agreement was signed following Foamix's successful development of non-steroidal foam which is designed to help skin barrier properties. Under the terms of the agreement, Foamix will be entitled to receive milestone payments upon achievement of various developments and commercial events and double-digit royalties.

"We are pleased to announce this license agreement with Foamix. Foamix has a proven track record of developing innovative dermatological foams and we are confident that this innovative product is a valuable addition to Ferndale's medications portfolio." said James T. McMillan II, Chief Executive Officer of, Ferndale.

Atopic Dermatitis (AD) is a common chronic inflammatory skin condition, affecting 15-20% of schoolchildren and 2-10% of adults. According to recent surveys, there are 17.8 million patients in the US and 46 million patients worldwide known to be affected. In the majority of patients, the disease begins in early childhood, often in the first year of life, when it can be particularly severe. The skin becomes extremely itchy; scratching leads to redness, swelling, cracking, "weeping" of clear fluid, and finally, crusting and scaling. The prolonged and continuous itching can lead to reduced attention, sustained sleep deprivation and scratching, which impairs the quality of life of the sufferer.

Poor adherence to AD therapy is common, and therefore, foams, which do not require extensive rubbing to achieve the necessary spreading and absorption, offer an improved treatment.

"This agreement with Ferndale further underscores Foamix's ability to convert technology into valuable product opportunities." said Foamix CEO, Dr. Dov Tamarkin. "In addition, this is one more step towards achieving Foamix's mission, improving the quality of patients' lives."

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a specialty pharmaceutical company focused on the development of topical foam products for prescription, OTC and cosmetic applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. We currently collaborate with 10 pharmaceutical companies on 12 projects in the development of proprietary dermatological and gynecologic foam drugs; and we have our own in-house pipeline of dermatological and gynecological drugs in foam presentation.

The company's development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing, preclinical and clinical studies. Foamix holds 4 US patents and has 65 US patents pending, with corresponding national applications worldwide.

For additional information please visit

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or

About Ferndale

Ferndale Laboratories specializes in high-value, brand name products that help relieve discomfort and promote healing for patients who show symptoms of inflammatory and pruritic cutaneous conditions.

The Company is dedicated to discovering, developing and delivering unique, value-added Dermatology therapies that help heal, protect and beautify the skin.


SOURCE Foamix Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
2. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
3. Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement
4. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
5. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
6. Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions
7. BMP Sunstone Receives Import Drug License (IDL) from SFDA
8. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical
11. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Cepheid (Nasdaq: CPHD ... at the Piper Jaffray Healthcare Conference in ... Company is reaffirming its outlook for the fourth quarter ... addition to discussing longer term business model expectations. ... Officer.  "We continue to be the fastest growing company ...
(Date:12/1/2015)... , December 1, 2015 ... of the  "2016 U.K. Virology and Bacteriology ... for 100 Tests, Supplier Shares by Test, ... to their offering.  --> ... "2016 U.K. Virology and Bacteriology Testing Market: ...
(Date:11/30/2015)... MIAMI (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group ... new clinics in the cities of Arica and Iquique in northern Chile. The facilities are ... clinics offer the most advanced protocols and techniques in stem cell medicine to patients from ...
(Date:11/30/2015)... ALBANY, N.Y. , Nov. 30, 2015 /PRNewswire-USNewswire/ ... led by assistant chemistry professor Jan Halámek, is ... level.   --> ...   --> ... researchers at UAlbany have discovered a straightforward concept ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):